The Transplant Forum at Columbia University Medical Center is dedicated to raising awareness and funding for transplantation research across all organ disciplines. To learn more about ongoing research in kidney and pancreas transplantation, please see several projects highlighted here:
Adult Kidney Transplant
David Cohen, MD, PhD
Under the leadership of Dr. David Cohen, Medical Director of CUMC’s Renal and Pancreatic Transplant Program, the kidney transplant team is on the verge of a major breakthrough that would revolutionize renal transplantation and vastly improve quality of life for patients. CUMC is ready to begin clinical trials of induced tolerance in kidney transplant recipients: that is, coaching a patient’s immune system to accept a transplanted kidney without the need for immunosuppression. By combining bone marrow and kidney transplantation from the same live donor, recipients will be able to discontinue all immunosuppression medications without fear of rejection or debilitating side effects. This will dramatically transform the lives of patients and their loved ones.
Krzysztof Kiryluk, MD
Columbia nephrology researcher Dr. Krzysztof Kiryluk is pursuing a new, genome-based approach to match prospective transplant patients with kidney donors. A precise match between patient and donor would potentially reduce the incidence of kidney rejection, improving transplant success rates and outcomes for patients. This work will help lay the foundation for a personalized approach to treating transplant patients.
Sumit Mohan, MD, MPH
Dr. Sumit Mohan is leading a multidisciplinary team to build a central clinical outcomes research data repository to facilitate clinical care and support robust epidemiological research using big data sciences approaches. This effort will provide insights into treatment strategies that can improve patient centered outcomes for transplant recipients while supporting data linkages to several other clinical research efforts across the transplant initiative.
Lloyd Ratner, MD, MPH
Dr. Lloyd Ratner leads a randomized, open-label multicenter trial to determine safety and efficacy of the drug eculizumab in the prevention of antibody mediated rejection (AMR) in living donor kidney transplant recipients requiring desensitization therapy. The purpose of the study is to determine if eculizumab is safe and could be used following desensitization therapy to prevent the condition AMR.